Multicenter phase II clinical trial of nilotinib for patients with imatinib-resistant or -intolerant chronic myeloid leukemia from the East Japan CML study group evaluation of molecular response and the efficacy and safety of nilotinib-Reference-Cited by-同舟云学术

Multicenter phase II clinical trial of nilotinib for patients with imatinib-resistant or -intolerant chronic myeloid leukemia from the East Japan CML study group evaluation of molecular response and the efficacy and safety of nilotinib

Published:2014-03-20 Issue:1 Volume:2 Page:
ISSN:2050-7771
Container-title:Biomarker Research
language:en
Short-container-title:Biomark Res

Author:

Takahashi Naoto,Miura Masatomo,Kuroki Jun,Mitani Kinuko,Kitabayashi Atsushi,Sasaki Osamu,Kimura Hideo,Imai Kiyotoshi,Tsukamoto Norifumi,Noji Hideyoshi,Kondo Takeshi,Motegi Mutsuhito,Kato Yuichi,Mita Masayuki,Saito Hajime,Yoshida Chikashi,Torimoto Yoshihiro,Kimura Tomofumi,Wano Yuji,Nomura Jun,Yamamoto Satoshi,Mayama Ko,Honma Riko,Sugawara Tomohiro,Sato Shinji,Shinagawa Atsushi,Abumiya Maiko,Niioka Takenori,Harigae Hideo,Sawada Kenichi

Publisher

Springer Science and Business Media LLC

Subject

Biochemistry (medical),Clinical Biochemistry,Molecular Medicine

Link

http://link.springer.com/content/pdf/10.1186/2050-7771-2-6.pdf

Reference31 articles.

1. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ, IRIS Investigators: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003, 348: 994–1004. 10.1056/NEJMoa022457

2. O’Brien SG, Guilhot F, Goldman JM, Hochhaus A, Hughes TP, Radich JP, Rudoltz M, Filian J, Gathmann I, Druker BJ, Larson RA: International Randomized Study of Interferon Versus STI571 (IRIS) 7-Year Follow-up: Sustained Survival, Low Rate of Transformation and Increased Rate of Major Molecular Response (MMR) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CMLCP) Treated with Imatinib (IM) [abstract]. Blood 2008, 112: 186.

3. Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, Cervantes F, Deininger M, Gratwohl A, Guilhot F, Hochhaus A, Horowitz M, Hughes T, Kantarjian H, Larson R, Radich J, Simonsson B, Silver RT, Goldman J, Hehlmann R, European LeukemiaNet: Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009, 27: 6041–6051. 10.1200/JCO.2009.25.0779

4. Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L, Goh YT, Rosti G, Nakamae H, Gallagher NJ, Hoenekopp A, Blakesley RE, Larson RA, Hughes TP: Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 2011, 12: 841–851. 10.1016/S1470-2045(11)70201-7

5. Kantarjian HM, Kim DW, Issaragrisil S, Clark RE, Reiffers J, Nicolini FE, Pasquini R, Kalaycio M, Hughes TP, Hochhaus A, Kemp C, Fan X, Waltzman RJ, Saglio G, Larson RA: Enestnd 4-year update: continued superiority of Nilotinib vs Imatinib in patients with newly diagnosed Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase [abstract]. Blood 2012, 120: 1676.

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Relationship between achievement of major molecular response or deep molecular response and nilotinib plasma concentration in patients with chronic myeloid leukemia receiving first-line nilotinib therapy;Cancer Chemotherapy and Pharmacology;2022-03-22

2. Differences in Variants in the Structural Domain of <b><i>BCR-ABL1</i></b> Kinase between Chinese Han and Minority Patients with Chronic Myeloid Leukemia by Sanger Sequencing and Next-Generation Sequencing;Cytogenetic and Genome Research;2022

3. Is dose modification or discontinuation of nilotinib necessary in nilotinib-induced hyperbilirubinemia?;World Journal of Meta-Analysis;2021-12-28

4. Tyrosine Kinase Inhibitors-Induced Arrhythmias: From Molecular Mechanisms, Pharmacokinetics to Therapeutic Strategies;Frontiers in Cardiovascular Medicine;2021-11-19

5. Evaluating the utility of therapeutic drug monitoring in the clinical use of small molecule kinase inhibitors: a review of the literature;Expert Opinion on Drug Metabolism & Toxicology;2021-07-03